The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Dyskinesias and motor fluctuations in Parkinson's disease
Abstract
We investigated the prevalence of dyskinesias and motor fluctuations, and the factors determining their occurrence, in a community-based population of patients with Parkinson's disease. Among 124 patients with Parkinson's disease, 87 (70%) had received a levodopa preparation. Among these 87 patients, 28% were experiencing treatment-induced dyskinesias and 40% response fluctuations. The prevalence of motor fluctuations was best predicted by disease duration and dose of levodopa, whereas dyskinesias could be best predicted by duration of treatment. Patients with a shorter time from symptom onset to initiation of levodopa and younger patients had developed motor complications earlier, and patients who had started treatment with a dopamine agonist had developed these treatment complications later. Although a satisfactory response to medication was associated with higher rates of motor complications, poor or moderate response was associated with lower quality of life in patients with a disease duration of </=5 years or >/=10 years. We conclude that motor fluctuations are most strongly related to disease duration and dose of levodopa, and dyskinesias to duration of levodopa treatment. However, poorer quality of life associated with inadequate dosage of levodopa may be the price for a low rate of motor complications in patients with Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Peto, V., Jenkinson, C., Fitzpatrick, R., & Greenhall, R. (1995) · Quality of Life Research · doi:10.1007/bf02260863 · Cited by 1,204
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
Schrag, A., Ben-Shlomo, Y., & Quinn, N. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04137-9 · Cited by 642
Self-citationBallard, P. A., Tetrud, J. W., & Langston, J. W. (1985) · Neurology · doi:10.1212/wnl.35.7.949 · Cited by 629
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE
Marsden, C. D., & Parkes, J. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91146-1 · Cited by 587
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Lesser, R. P., Fahn, S., Snider, S. R., Cote, L. J., Isgreen, W. P., & Barrett, R. E. (1979) · Neurology · doi:10.1212/wnl.29.9_part_1.1253 · Cited by 319
THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE
GIBB, W. R. G., & LEES, A. J. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01147.x · Cited by 319
Kostic, V., Przedborski, S., Flaster, E., & Sternic, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 297
Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London
Schrag, A., Ben-Shlomo, Y., & Quinn, N. P. (2000) · BMJ · doi:10.1136/bmj.321.7252.21 · Cited by 252
Self-citationComparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease
Block, G., Liss, C., Reines, S., Irr, J., & Nibbelink, D. (1997) · European Neurology · doi:10.1159/000117399 · Cited by 234
Montastruc, J. L., Rascol, O., Senard, J. M., & Rascol, A. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1034 · Cited by 198
The epidemiology of Parkinson's disease in the county of Rogaland, Norway
Tandberg, E., Larsen, J. P., Nessler, E. G., Riise, T., & Aarli, J. A. (1995) · Movement Disorders · doi:10.1002/mds.870100503 · Cited by 177
Gender differences in Parkinson's disease.
Lyons, K. E., Hubble, J. P., Tröster, A. I., Pahwa, R., & Koller, W. C. (1998) · PubMed · Cited by 177
SWEET, R. D., & McDOWELL, F. H. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-456 · Cited by 172
Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease
Rinne, U. K. (1987) · Neurology · doi:10.1212/wnl.37.5.826 · Cited by 166
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.
Lees, A. J., & Stern, G. M. (1981) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.44.11.1020 · Cited by 163
Low‐dose L‐dopa therapy in Parkinson's disease: A 6‐year follow‐up study
Poewe, W. H., Lees, A. J., & Stern, G. M. (1986) · Neurology · doi:10.1212/wnl.36.11.1528 · Cited by 163
Hely, M. A., Morris, J. G., Reid, W., O'Sullivan, D. J., Williamson, P. M., Rail, D., Broe, G. A., & Margrie, S. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.8.903 · Cited by 154
Long‐term follow‐up of early dopa treatment in Parkinson's disease
Markham, C. H., & Diamond, S. G. (1986) · Annals of Neurology · doi:10.1002/ana.410190410 · Cited by 109
Dupont, E., Andersen, A., Boas, J., et al. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb00163.x · Cited by 108
Cedarbaum, J. M., Gandy, S., & MCDOWELL, F. H. (1991) · Neurology · doi:10.1212/wnl.41.5.622 · Cited by 108
Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage
Schneider, J. S. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90372-9 · Cited by 108
Factors that influence the occurrence of response variations in Parkinson's disease
de Jong, G. J., Meerwaldt, J. D., & Schmitz, P. I. M. (1987) · Annals of Neurology · doi:10.1002/ana.410220104 · Cited by 107
Does levodopa aggravate Parkinson's disease?
Blin, J., Bonnet, A.-M., & Agid, Y. (1988) · Neurology · doi:10.1212/wnl.38.9.1410 · Cited by 103
Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel Monkeys
Boyce, S., Rupniak, N. M. J., Steventon, M. J., et al. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199010000-00006 · Cited by 101
Should Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment
Fahn, S., & Bressman, S. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046412 · Cited by 101
The initial treatment of Parkinson's disease should begin with levodopa
Weiner, W. J. (1999) · Movement Disorders · Cited by 58
Motor fluctuations in Parkinson’s disease
Denny, A. P., & Behari, M. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00052-0 · Cited by 57
Response fluctuations in Parkinson's disease
Roos, R. A. C., VREDEVOOGD, C. B., & van der Velde, E. A. (1990) · Neurology · doi:10.1212/wnl.40.9.1344 · Cited by 35
Cited by
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
Rodriguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J.-L., Pollak, P., Rehncrona, S., Kulisevsky, J., Albanese, A., Volkmann, J., Hariz, M. I., et al. (2005) · Brain · doi:10.1093/brain/awh571 · Cited by 1,057
Self-citationThe scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
A review of Parkinson's disease
Davie, C. A. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn013 · Cited by 855
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Parkinson's disease symptoms: The patient's perspective
Politis, M., Wu, K., Molloy, S., G. Bain, P., Chaudhuri, K. R., & Piccini, P. (2010) · Movement Disorders · doi:10.1002/mds.23135 · Cited by 647
Metadata
- Authors
- Schrag, A., & Quinn, N.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-11
- Volume
- 123
- Issue
- 11
- Pages
- 2297-2305
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2034825135
- Cited by
- 600
- References
- 34
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.